Replicor Inc.

7 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Aug 2031

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Mar 15, 2027
The maintenance fee for Methods for the treatment of hepatitis B and hepatitis D infections (US 9,133,458) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
1 fee due Jun 1, 2027
The maintenance fee for Methods for the treatment of hepatitis B and hepatitis D infections (US 9,200,283) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
1 fee due Sep 15, 2027
The maintenance fee for Methods for the treatment of hepatitis B and hepatitis D infections (US 9,284,556) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 7 of 7

Patent	Title	Status	Expires	Confidence
US 8,513,211	Oligonucleotide chelate complexes In force Term ends Aug 18, 2031 · From the USPTO record	In force	Term ends Aug 18, 2031	From the USPTO record
US 8,716,259	Oligonucleotide chelate complexes In force Term ends Aug 18, 2031 · From the USPTO record	In force	Term ends Aug 18, 2031	From the USPTO record
US 9,200,283	Methods for the treatment of hepatitis B and hepatitis D infections In force Ends no later than May 17, 2033 · From the USPTO record	In force	Ends no later than May 17, 2033	From the USPTO record
US 9,284,556	Methods for the treatment of hepatitis B and hepatitis D infections In force Ends no later than May 17, 2033 · From the USPTO record	In force	Ends no later than May 17, 2033	From the USPTO record
US 9,533,003	Methods for the treatment of hepatitis B and hepatitis D infections In force Term ends May 17, 2033 · From the USPTO record	In force	Term ends May 17, 2033	From the USPTO record
US 9,133,458	Methods for the treatment of hepatitis B and hepatitis D infections In force Term ends Sep 11, 2033 · From the USPTO record	In force	Term ends Sep 11, 2033	From the USPTO record
US 9,492,506	Oligonucleotide chelate complex—polypeptide compositions and methods In force Term ends Apr 6, 2034 · From the USPTO record	In force	Term ends Apr 6, 2034	From the USPTO record

Also on record, not counted in the 7: 5 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 8 no status recorded

List them